Under the terms of the accelerated share repurchase, MEDNAX will repurchase $200 million of its common stock, with an aggregate initial delivery of approximately 2.5 million shares. The final settlement of the transactions under the ASR agreement is expected to occur in up to seven months.
The ASR program is being executed as part of an authorization by the company’s board of directors to repurchase up to $600 million of the company’s common stock, announced on Oct. 30.
More articles in anesthesia:
NAPA to provide exclusive anesthesia services at Southington Surgery Center
U.S. anesthesia drugs market to reach $3B+ by 2018: 3 key points
NAPA Dr. Joseph Marino to study treatment for postoperative pain relief
